The effect of prophylactic topical steroid cream on the incidence and severity of cutaneous burns following external DC cardioversion

Resuscitation. 2005 May;65(2):179-84. doi: 10.1016/j.resuscitation.2004.11.014. Epub 2005 Jan 15.

Abstract

Introduction: Cutaneous burns are a common cause of morbidity following direct current (DC) cardioversion. We designed a prospective double-blinded controlled study to determine whether the application of steroid cream prior to cardioversion reduces their incidence and severity.

Materials and methods: Two hours before elective DC cardioversion, we applied betamethasone 0.1% cream or placebo cream over sternal and apical pad sites in 56 patients, with patients acting as their own controls. Two hours after cardioversion, a separate blinded observer measured the visual analogue pain score (VAS), sensory and pain detection thresholds, skin temperature and erythema index at sternal and apical pad sites.

Results: The study had an 80% power to detect a 50% difference in VAS at 2 h, accepting an alpha error of 0.05. There was no difference between pain at 2 or 24 h, skin temperature, erythema index, sensory and pain detection thresholds at pad sites treated with steroid cream or control.

Conclusion: Topical betamethasone 0.1% cream applied 2 h before elective DC cardioversion is no more effective than placebo at reducing the pain and inflammation from cardioversion burns.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Betamethasone / administration & dosage*
  • Burns, Electric / etiology*
  • Burns, Electric / prevention & control*
  • Double-Blind Method
  • Electric Countershock / adverse effects*
  • Erythema / drug therapy
  • Erythema / etiology
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Male
  • Pain / drug therapy
  • Pain / etiology
  • Pain Threshold / drug effects
  • Prospective Studies
  • Skin Temperature / drug effects
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Betamethasone